Home Medical Devices Large Molecule Drug Substance CDMO Market Size & Demand | 2033

Large Molecule Drug Substance CDMO Market Size & Outlook, 2025-2033

Large Molecule Drug Substance CDMO Market Size, Share & Trends Analysis Report By Service (Contract Manufacturing, Contract Development), By Source (Mammalian, Microbial, Others), By End-user (Biotech Companies, CRO, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRMD1787DR
Last Updated : May, 2025
Pages : 110
Author : Jay Mehta
Format : PDF, Excel

Table Of Content

  1. Executive Summary

    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends

    1. Global Large Molecule Drug Substance CDMO Market Introduction
    2. By Service
      1. Introduction
        1. Service By Value
      2. Contract Manufacturing
        1. By Value
      3. Contract Development
        1. By Value
    3. By Source
      1. Introduction
        1. Source By Value
      2. Mammalian
        1. By Value
      3. Microbial
        1. By Value
      4. Others
        1. By Value
    4. By End-user
      1. Introduction
        1. End-user By Value
      2. Biotech Companies
        1. By Value
      3. CRO
        1. By Value
      4. Others
        1. By Value
    1. Introduction
    2. By Service
      1. Introduction
        1. Service By Value
      2. Contract Manufacturing
        1. By Value
      3. Contract Development
        1. By Value
    3. By Source
      1. Introduction
        1. Source By Value
      2. Mammalian
        1. By Value
      3. Microbial
        1. By Value
      4. Others
        1. By Value
    4. By End-user
      1. Introduction
        1. End-user By Value
      2. Biotech Companies
        1. By Value
      3. CRO
        1. By Value
      4. Others
        1. By Value
    5. U.S.
      1. By Service
        1. Introduction
          1. Service By Value
        2. Contract Manufacturing
          1. By Value
        3. Contract Development
          1. By Value
      2. By Source
        1. Introduction
          1. Source By Value
        2. Mammalian
          1. By Value
        3. Microbial
          1. By Value
        4. Others
          1. By Value
      3. By End-user
        1. Introduction
          1. End-user By Value
        2. Biotech Companies
          1. By Value
        3. CRO
          1. By Value
        4. Others
          1. By Value
    6. Canada
    1. Introduction
    2. By Service
      1. Introduction
        1. Service By Value
      2. Contract Manufacturing
        1. By Value
      3. Contract Development
        1. By Value
    3. By Source
      1. Introduction
        1. Source By Value
      2. Mammalian
        1. By Value
      3. Microbial
        1. By Value
      4. Others
        1. By Value
    4. By End-user
      1. Introduction
        1. End-user By Value
      2. Biotech Companies
        1. By Value
      3. CRO
        1. By Value
      4. Others
        1. By Value
    5. U.K.
      1. By Service
        1. Introduction
          1. Service By Value
        2. Contract Manufacturing
          1. By Value
        3. Contract Development
          1. By Value
      2. By Source
        1. Introduction
          1. Source By Value
        2. Mammalian
          1. By Value
        3. Microbial
          1. By Value
        4. Others
          1. By Value
      3. By End-user
        1. Introduction
          1. End-user By Value
        2. Biotech Companies
          1. By Value
        3. CRO
          1. By Value
        4. Others
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Service
      1. Introduction
        1. Service By Value
      2. Contract Manufacturing
        1. By Value
      3. Contract Development
        1. By Value
    3. By Source
      1. Introduction
        1. Source By Value
      2. Mammalian
        1. By Value
      3. Microbial
        1. By Value
      4. Others
        1. By Value
    4. By End-user
      1. Introduction
        1. End-user By Value
      2. Biotech Companies
        1. By Value
      3. CRO
        1. By Value
      4. Others
        1. By Value
    5. China
      1. By Service
        1. Introduction
          1. Service By Value
        2. Contract Manufacturing
          1. By Value
        3. Contract Development
          1. By Value
      2. By Source
        1. Introduction
          1. Source By Value
        2. Mammalian
          1. By Value
        3. Microbial
          1. By Value
        4. Others
          1. By Value
      3. By End-user
        1. Introduction
          1. End-user By Value
        2. Biotech Companies
          1. By Value
        3. CRO
          1. By Value
        4. Others
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Service
      1. Introduction
        1. Service By Value
      2. Contract Manufacturing
        1. By Value
      3. Contract Development
        1. By Value
    3. By Source
      1. Introduction
        1. Source By Value
      2. Mammalian
        1. By Value
      3. Microbial
        1. By Value
      4. Others
        1. By Value
    4. By End-user
      1. Introduction
        1. End-user By Value
      2. Biotech Companies
        1. By Value
      3. CRO
        1. By Value
      4. Others
        1. By Value
    5. UAE
      1. By Service
        1. Introduction
          1. Service By Value
        2. Contract Manufacturing
          1. By Value
        3. Contract Development
          1. By Value
      2. By Source
        1. Introduction
          1. Source By Value
        2. Mammalian
          1. By Value
        3. Microbial
          1. By Value
        4. Others
          1. By Value
      3. By End-user
        1. Introduction
          1. End-user By Value
        2. Biotech Companies
          1. By Value
        3. CRO
          1. By Value
        4. Others
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Service
      1. Introduction
        1. Service By Value
      2. Contract Manufacturing
        1. By Value
      3. Contract Development
        1. By Value
    3. By Source
      1. Introduction
        1. Source By Value
      2. Mammalian
        1. By Value
      3. Microbial
        1. By Value
      4. Others
        1. By Value
    4. By End-user
      1. Introduction
        1. End-user By Value
      2. Biotech Companies
        1. By Value
      3. CRO
        1. By Value
      4. Others
        1. By Value
    5. Brazil
      1. By Service
        1. Introduction
          1. Service By Value
        2. Contract Manufacturing
          1. By Value
        3. Contract Development
          1. By Value
      2. By Source
        1. Introduction
          1. Source By Value
        2. Mammalian
          1. By Value
        3. Microbial
          1. By Value
        4. Others
          1. By Value
      3. By End-user
        1. Introduction
          1. End-user By Value
        2. Biotech Companies
          1. By Value
        3. CRO
          1. By Value
        4. Others
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Large Molecule Drug Substance CDMO Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Eurofins Scientific
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. WuXi Biologics
    3. Samsung Biologics
    4. Catalent, Inc.
    5. Cambrex Corp.
    6. AGC Biologics
    7. Recipharm AB (publ)
    8. Siegfried Holding AG
    9. LabCorp Drug Development, and FUJIFILM Diosynth Biotechnologies
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Available for purchase with detailed segment data, forecasts, and regional insights.

Get This Report

Download Free Sample

Note: Please ensure you provide an active email address as we will be sending sample details via email.
The button will be active once the above form is filled

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on :